hotspot -WSS

hotspot

author：focus 2025-09-06 06:16:32 - browse：1994

This is the inaugural edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.

Hello! Welcome to the premiere issue of Adam’s Biotech Scorecard. I’m excited to get started. Let’s do this! (By the way, the AF in the logo are my initials, not the “other” AF.)

The contrarian view of Viking Therapeutics

Closeup financial chart

The developer of a dual-acting GLP-1/GIP treatment for obesity is riding high on positive data and takeout speculation. The drug, called VK2735, has shown impressive weight loss with minimal gastrointestinal side effects in both subcutaneous and oral formulations, positioning it as a strong challenger to the obesity juggernauts from Eli Lilly and Novo Nordisk. With a stock price that has soared nearly 800% over the past year, Viking is now a $9 billion company and a prime acquisition target for a cash-rich pharma company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： All of Us, NIH's precision medicine initiative, gets a big boost

focus

WSS

The problems with dementia villages

Roivant's CEO is a star, but biotech's black hole persists

Why a market frenzy over new weight loss drugs defies logic

Travis Kelce and the trap of celebrity vaccine endorsements

Medicare must police algorithms in Medicare Advantage, Dems say

Life sciences investors close nearly $6 billion in new funds

Wikipedia

hotspot

The contrarian view of Viking Therapeutics

leisure time

Anesthesiologist group: stop taking Ozempic before surgery

Key Senate panel to consider PBM, drug pricing reform package

Medical leaders decry Supreme Court decision on affirmative action

The problems with dementia villages

Malaria cases in Florida and Texas: Here’s what you need to know

Explaining an after

Medicare proposal to cover medical devices draws a mixed reaction

CZI to create biohub to build anti

At least 13 dead in Texas as scorching temps continue

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

explore

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Brain injuries and the importance of a second opinion

Readout LOUD podcast: Live from the 2023 STAT Summit

Lung cancer screening guidelines updated for cigarette smokers

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

All of Us, NIH's precision medicine initiative, gets a big boost

explore

focus

hotspot

explore